在心肌梗塞后使用维护喷射分数的β抑制剂:系统性审查和元分析
Rafael Alessandro Ferreira Gomes1, Ludmila Cristina Camilo Furtado1, Marcela Vasconcelos Montenegro1
1Department of Cardiology, University of Pernambuco, Recife, PE, Brazil.
Cardiovascular diagnosis and therapy
|May 19, 2025
概括
在心肌梗塞 (MI) 后,长期使用β-阻塞剂 (BB) 在保留喷射分数的患者中并没有显著降低死亡率. 进一步分析显示,再发心脏病发作,心力衰竭住院治疗或中风没有益处.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 心肌梗塞 (MI) 是全球主要的死亡原因.
- β抑制剂 (BBs) 是MI后的标准治疗方法.
- 在保持左心室喷射分数 (LVEF) 的患者中,BBs的长期疗效尚不清楚.
研究的目的:
- 系统地审查和元分析长期BB使用对MI患者的死亡率的影响.
- 在这个特定的患者群体中,综合证据证明BBs对心血管结果的影响.
主要方法:
- 系统审查和元分析遵循柯克兰和PRISMA指南.
- 在Embase,Cochrane Central和PubMed搜索到2024年9月1日之前的英语研究.
- 提取了所有原因死亡率,心血管疾病死亡,心肌梗塞,中风和心力衰竭 (HF) 住院的数据.
- 使用ROBINS-I和RoB2工具评估偏差风险.
- 时间到事件数据的聚合危险比率 (HRs).
主要成果:
- 包括11项研究,85,607名患者; 76.8%使用BBs.
- 最初的分析显示,BBs的全因死亡率显著降低 (HR=0.81,P=0.03).
- 然而,灵敏度分析表明,这种减少并不显著 (HR=0.79,P=0.07).
- 在复发性心脏病发作 (HR=1.00,P>0.99),高频率住院 (HR=1.05,P=0.55) 或中风 (具有异质性) 方面没有发现显著差异.
- 根据年龄,性别,高血压或糖尿病的子组分析显示,结果没有差异.
结论:
- 长期使用β-阻断剂在患有保存LVEF后心脏病发作的患者中,并没有显示出任何原因死亡率的显著降低.
- 没有观察到心血管死亡率,MACE,HF住院,MI或中风的显著下降.
- 这些发现表明,目前的证据不支持在这个患者群体中针对这些特定结果的常规长期BB使用.
相关概念视频
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...